Impact of Apollo Wearable on Long COVID Symptoms
Effect of Apollo Wearable on Symptoms Related to Post-acute Sequelae SARS-CoV-2 Infection (PASC).
This study is testing whether using the Apollo wearable device can help people with long COVID feel better and improve their quality of life.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The Board of Medicine Academic / other |
| Locations | 1 site (Pittsburgh, Pennsylvania) |
| Trial ID | NCT06097442 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate how the use of the Apollo wearable device affects symptoms and quality of life in individuals suffering from long COVID, also known as post-acute sequelae of SARS-CoV-2 infection (PASC). Participants will include new purchasers of the Apollo device or previous users who have not used it in the last 14 days and are currently experiencing long COVID symptoms. The study will involve administering clinically validated surveys to assess baseline symptoms and quality of life, followed by monthly surveys over six months to track changes. Data on wearable usage will also be collected for analysis.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and over who are experiencing symptoms related to long COVID and have recently purchased or previously used the Apollo device.
Not a fit: Patients who are unable to use a compatible smartphone or those who do not speak English may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into a non-invasive method to alleviate long COVID symptoms and improve quality of life for affected patients.
How similar studies have performed: While there is limited evidence for effective treatments for long COVID, the use of wearable technology for symptom management is a novel approach that has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * New purchasers of Apollo who haven't started using their Apollo device or previous users of Apollo who haven't used Apollo in the preceding 14 days. * Age 18 years or over * Currently experiencing symptoms related to long-COVID according to PASC (self report). * Must be experiencing PASC symptoms in at least one of the following domains: Respiratory-related symptoms Fatigue-related symptoms Neurologic-related symptoms Psychiatric-related symptoms Sleep-related symptoms Change in quality of life/functional status Exclusion Criteria: * Inability to use or access a compatible Android or iOS smartphone * Are unable to complete consent and questionnaires written in English * Current resident of a European Union (EU) country
Where this trial is running
Pittsburgh, Pennsylvania
- The Board of Medicine — Pittsburgh, Pennsylvania, United States (Recruiting)
Study contacts
- Study coordinator: Belinda Tan, MD, PhD
- Email: belinda@theboardofmedicine.org
- Phone: 4129450345
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.